Clinical Research Papers:
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
Metrics: PDF 1050 views | HTML 1775 views | ?
Jingqi Zhuang1, Yongfeng Yu1, Ziming Li1 and Shun Lu1
1 Department of Oncology, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, People’s Republic of China
Shun Lu, email:
Keywords: efficacy, lung squamous cell carcinoma, epidermal growth factor receptor mutation, tyrosine kinase inhibitors, pooled analysis
Received: January 02, 2017 Accepted: February 01, 2017 Published: February 25, 2017
Purpose: This pooled analysis aims to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in lung squamous cell carcinoma with EGFR mutation.
Methods: Advanced stage (IIIB/IV) lung squamous cell carcinoma patients with EGFR mutations treated with EGFR-TKIs were extracted from the publications searched from the databases of EMBASE, Medline (Ovid SP), Web of Science, Cochrane library, PubMed Publisher, ASCO meeting abstract and Google Scholar before August 2016, or identified from the database of Shanghai Chest Hospital from July 2014 to August 2016. Pooled objective response rate, disease control rate and median progression-free survival were accessed directly or by Kaplan-Meier method and combined in different studies by Comprehensive Meta Analysis software via one-group dichotomous or continuous analysis functions.
Results: The combined objective response rate, disease control rate and median progression-free survival were 31.6% (95%CI, 24.1%~40.2%), 72.0% (95% CI, 63.5%~79.2%) and 3.08 months (95% CI, 2.31-3.84 months) in lung squamous cell carcinoma patients with EGFR mutation.
Conclusion: The EGFR-TKIs had a modest response for EGFR mutated lung squamous cell carcinoma patients and might be a selective option for those patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.